BridGene Biosciences Inc is a biomedical company focused on the discovery and development of covalent small-molecule inhibitors -- innovative small molecules that drug high value yet previously undruggable targets, providing new paths to treat diseases. Currently, an estimated 90% of proteins associated with diseases cannot be targeted by traditional therapies due to the lack of a known addressable binding site. BridGene is addressing this limitation by using its proprietary Chemoproteomics platform, IMTAC™ (Isobaric Mass Tagged Affinity Characterization). IMTAC™ enables the screening of small molecules against all the proteins in live cells to discover drug candidates for high value and hard-to-drug targets that cause diseases. Bringing new drugs to previously undruggable targets means new therapies with new mechanisms for unmet medical needs -with the ultimate goal being to expand small molecule drug discovery approaches and scope at an unprecedented speed and success rate. The company uses two primary tools for the discovery of covalent drugs: IMTACTM, a chemical proteomic platform to discover the druggable opportunities across the entire proteome; and Target-Orientated Discovery to developcovalent drugs to overcome drug resistance and expand the druggable spaces to targets with shallow binding pockets.
